Target identification by image analysis.
暂无分享,去创建一个
F. Sasse | M. Brönstrup | V. Fetz | F Sasse | H. Prochnow | V Fetz | H Prochnow | M Brönstrup | Hans Prochnow
[1] Erin E. Carlson,et al. Natural products as chemical probes. , 2010, ACS chemical biology.
[2] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[3] S. Zahler,et al. Photoswitchable Inhibitors of Microtubule Dynamics Optically Control Mitosis and Cell Death , 2015, Cell.
[4] Yasser A. Elnakady,et al. Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. , 2004, Biochemical pharmacology.
[5] H. Reichenbach,et al. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. , 2000, The Journal of antibiotics.
[6] I. Vorobjev,et al. Imaging Flow Cytometry , 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[7] F. Mollinedo,et al. Microtubules, microtubule-interfering agents and apoptosis , 2003, Apoptosis.
[8] E. Lazarides,et al. Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway , 1995, Molecular medicine.
[9] H. Reichenbach,et al. Myxothiazol, a new inhibitor of the cytochrome b-c1 segment of th respiratory chain. , 1981, Biochimica et biophysica acta.
[10] J. Ellenberg,et al. High-throughput fluorescence microscopy for systems biology , 2006, Nature Reviews Molecular Cell Biology.
[11] H. Reichenbach,et al. Disorazol A, an efficient inhibitor of eukaryotic organisms isolated from myxobacteria. , 1995, The Journal of antibiotics.
[12] H. Reichenbach,et al. The chondramides: cytostatic agents from myxobacteria acting on the actin cytoskeleton. , 1998, Journal of the National Cancer Institute.
[13] Thomas Böttcher,et al. Natural products and their biological targets: proteomic and metabolomic labeling strategies. , 2010, Angewandte Chemie.
[14] D Lansing Taylor,et al. Past, present, and future of high content screening and the field of cellomics. , 2007, Methods in molecular biology.
[15] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[16] H. Erfle,et al. High-throughput RNAi screening by time-lapse imaging of live human cells , 2006, Nature Methods.
[17] R. Olsen,et al. Identification of Direct Protein Targets of Small Molecules , 2010, ACS chemical biology.
[18] H. Matter,et al. Targeting DnaN for tuberculosis therapy using novel griselimycins , 2015, Science.
[19] Gábor J. Székely,et al. Hierarchical Clustering via Joint Between-Within Distances: Extending Ward's Minimum Variance Method , 2005, J. Classif..
[20] Albert Gough,et al. High-Content Screening: A New Approach to Easing Key Bottlenecks in the Drug Discovery Process , 1997 .
[21] Lani F. Wu,et al. Characterizing heterogeneous cellular responses to perturbations , 2008, Proceedings of the National Academy of Sciences.
[22] M. Jordan,et al. The taccalonolides and paclitaxel cause distinct effects on microtubule dynamics and aster formation , 2014, Molecular Cancer.
[23] Lani F. Wu,et al. Image-based multivariate profiling of drug responses from single cells , 2007, Nature Methods.
[24] H. Steinmetz,et al. Archazolid and apicularen: Novel specific V-ATPase inhibitors , 2005, BMC Biochemistry.
[25] H. Reichenbach,et al. Chivosazoles A and F, Cytostatic Macrolides from Myxobacteria, Interfere with Actin , 2009, Chembiochem : a European journal of chemical biology.
[26] M. Uhlik,et al. High-content multiplexed tissue imaging and quantification for cancer drug discovery. , 2013, Drug discovery today.
[27] Daniel Rauh,et al. An Unbiased Cell Morphology–Based Screen for New, Biologically Active Small Molecules , 2005, PLoS biology.
[28] D. L. Taylor,et al. Advances in high content screening for drug discovery. , 2003, Assay and drug development technologies.
[29] G. Terstappen,et al. Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.
[30] Stefano Forli. Epothilones: From discovery to clinical trials. , 2014, Current topics in medicinal chemistry.
[31] S. Feinstein,et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. , 2009, Chemistry & biology.
[32] Herbert Waldmann,et al. Target identification for small bioactive molecules: finding the needle in the haystack. , 2013, Angewandte Chemie.
[33] Aabid Shariff,et al. Automated Image Analysis for High-Content Screening and Analysis , 2010, Journal of biomolecular screening.
[34] S. Haggarty,et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.
[35] Neil O Carragher,et al. High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells , 2010, Molecular Cancer Therapeutics.
[36] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[37] A. J. North,et al. Seeing is believing? A beginners' guide to practical pitfalls in image acquisition , 2006, The Journal of cell biology.
[38] P. Srivastava,et al. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. , 2007, Immunity.
[39] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[40] D L Taylor,et al. Real-time molecular and cellular analysis: the new frontier of drug discovery. , 2001, Current opinion in biotechnology.
[41] Anne E Carpenter,et al. Comparison of Methods for Image-Based Profiling of Cellular Morphological Responses to Small-Molecule Treatment , 2013, Journal of biomolecular screening.
[42] Jie Hu,et al. Technological Advances in High-Throughput Screening , 2004, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[43] Wolfgang Link,et al. High content screening: seeing is believing. , 2010, Trends in biotechnology.
[44] Lani F. Wu,et al. Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.
[45] K. Marks,et al. The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes , 2011, Journal of natural products.
[46] H. Sahl,et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics , 2005, Nature Medicine.
[47] Cynthia L Adams,et al. Compound classification using image-based cellular phenotypes. , 2006, Methods in enzymology.
[48] S. Hell,et al. Fluorogenic probes for live-cell imaging of the cytoskeleton , 2014, Nature Methods.
[49] Yasser A. Elnakady,et al. Mechanism of Action of Tubulysin, an Antimitotic Peptide from Myxobacteria , 2006, Chembiochem : a European journal of chemical biology.
[50] E. Lazarides,et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.
[51] C. Rugg,et al. Identifying Small Molecules which Inhibit Autophagy: a Phenotypic Screen Using Image-Based High-Content Cell Analysis , 2014, Current chemical genomics and translational medicine.
[52] John A. Tallarico,et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.
[53] B. Kunze,et al. Total synthesis and biological activity of neopeltolide and analogues. , 2008, Chemistry.
[54] K. Pogliano,et al. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules , 2013, Proceedings of the National Academy of Sciences.
[55] H. Wieczorek,et al. Cruentaren A, a highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1‐ATPases , 2007, FEBS letters.
[56] John A. Tallarico,et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.